Diseases

JNJ-6143, an investigational first-in-class oral molecule, produced a 75% tumor response rate among patients with measurable disease in a Phase 1 study. #SyenzaNews #prostatecancer #oncology

Sone-Ve doubled median overall survival versus investigator's choice in third-line and later gastro-oesophageal cancer; second-line PFS missed significance.

Portaria n.º 464/2026/1 limits state reimbursement for obesity medicines to SNS patients in a hospital obesity pathway. Cover is 15% for 12 months. #SyenzaNews #MarketAccess

A Pretoria court has declared invalid the antiretroviral tender awards for two items and ordered the health department to redo the split within 120 days. Cipla's review succeeded on all five grounds, while Hetero's challenge was dismissed with attorney-and-client costs. #SyenzaNews #SouthAfrica #HIV

Merck and Moderna report a 42% reduction in recurrence or death for intismeran plus KEYTRUDA in resected stage IIB-IV melanoma, with full data at ESMO 2026. #SyenzaNews #melanoma #MarketAccess

The FDA has launched the Neuroscience Advancement and Innovation Nexus, starting with an Alzheimer's Prevention Accelerator. #SyenzaNews #Alzheimers #MarketAccess

Pfizer has withdrawn its EU application for palbociclib in HER2-positive breast cancer. EMA questioned the open-label PATINA endpoint.

Two post hoc REDEFINE 1 analyses show CagriSema weight loss in women held across premenopausal, perimenopausal and postmenopausal stages. #SyenzaNews #obesity #MarketAccess

A new biomarker laboratory in Portugal opens on 21 October at the University of Porto, funded with 2.1 million euros from the PRR. #SyenzaNews #biomarkers #precisionmedicine

Gilead's once-daily oral emvistegrast met the primary endpoint in Phase 2 SWIFT ulcerative colitis data, with 66% clinical response at Week 12 versus 37% on placebo. #SyenzaNews #biotechnology #MarketAccess

FDA grants accelerated approval for Jemperli in locally advanced rectal cancer, based on interim AZUR-1 results. #SyenzaNews #oncology #MarketAccess

Infarmed has logged 695 suspected adverse reactions to GLP-1 drugs in Portugal since 2024, most linked to Mounjaro.